去纤苷国内的价格

Defibrotide (defiteli) has the effects of anticoagulation, promoting fibrinolysis, and also promotes vascularization. Basic fibroblast growth factor (bFGF) has the effect of stimulating vascularization. Some studies have found that defibrotide can not only combine with basic fibroblast growth factor (bFGF) to mobilize bFGF from the extracellular matrix, but can also protect bFGF from protease degradation, thereby stimulating angiogenesis.

Defibrotide (defiteli) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defibrotide was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States on March 30, 2016, under the trade name Defitelio.

Defibrotide (defiteli) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Has it been launched in China? What's the price?

It is understood that defibrotide (defiteli) has not been approved for marketing in my country, so there is no domestic price. The current price of defibrotide is around $28,000, and patients can go directly to the United States to buy American defibrotide. In addition, defibrotide is also available in Hong Kong, my country, but the price in Hong Kong is usually almost the same as the international price. Patients can buy it in person, or contact Medical Companion Travel for more information on purchasing defibrotide.

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. The development and launch of defibrotide has brought new hope for the treatment of HVOD patients.